Mirpresoc (Telmisartan)

Telmisartan is an angiotensin II receptor blocker used to manage conditions related to the renin‑angiotensin system.

• Hypertension: lowers systolic and diastolic blood pressure, reducing the risk of stroke and heart attack.
• Cardiovascular risk reduction: decreases incidence of major cardiovascular events in patients with hypertension who are at high risk.
• Diabetic nephropathy (adjunct): slows progression of renal impairment in type 2 diabetes when combined with standard care.

• Telmisartan selectively blocks the angiotensin II type 1 (AT₁) receptor, preventing angiotensin II from binding and activating the receptor. This inhibition stops vasoconstriction and aldosterone release, leading to relaxation of vascular smooth muscle, reduced peripheral resistance, and decreased sodium and water retention, which together lower arterial blood pressure. The drug’s high affinity for the AT₁ receptor provides sustained blood pressure control with once‑daily dosing and minimal effect on the AT₂ receptor, preserving beneficial vasodilatory pathways.

Telmisartan may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects

• Dizziness: sensation of light‑headedness, especially after the first dose.
• Headache: mild to moderate intensity.
• Fatigue: feeling of tiredness or lack of energy.
• Back pain: discomfort in the lumbar region.
• Nasal congestion: blocked or runny nose.
• Diarrhea: loose stools occurring intermittently.

Serious or Rare Side Effects

• Angioedema: swelling of the face, lips, tongue or throat requiring immediate medical attention.
• Hyperkalemia: elevated blood potassium levels that may cause cardiac arrhythmia.
• Acute renal failure: sudden loss of kidney function, indicated by reduced urine output.
• Hepatic injury: signs of liver dysfunction such as jaundice or elevated enzymes.
• Severe hypotension: marked drop in blood pressure leading to fainting.

Before initiating telmisartan therapy, certain precautions should be observed to ensure patient safety.

• Monitor blood pressure: verify adequate control and avoid excessive hypotension.
• Assess renal function: check serum creatinine and eGFR prior to treatment and periodically thereafter.
• Check electrolytes: especially potassium levels to detect hyperkalemia.
• Avoid use in pregnancy: telmisartan is contraindicated due to risk of fetal toxicity.
• Use caution in hepatic impairment: dose adjustment may be required in patients with liver disease.
• Store at room temperature: keep below 25 °C in the original packaging, protected from moisture and light.

Telmisartan can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Aliskiren (in diabetic patients): combined use may increase risk of renal impairment, hyperkalemia and hypotension.
• Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous elevations in serum potassium.
• ACE inhibitors: concurrent use raises the likelihood of angioedema and hyperkalemia.
• Lithium: telmisartan can increase lithium concentrations, leading to toxicity.
• NSAIDs (high‑dose): may reduce antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely)

• Thiazide diuretics: may enhance blood‑pressure‑lowering effect, requiring dose adjustment.
• Other antihypertensives: additive hypotensive effect may occur.
• CYP2C9 inhibitors (e.g., fluconazole): can increase telmisartan plasma levels.
• Antidiabetic agents: monitor glucose control as blood pressure changes may affect insulin sensitivity.